We evaluated four representative chemotherapy regimens for unresectable advanced or recurrent KRAS-wild type colorectal cancer: mFOLFOX6, mFOLFOX6＋bevacizumab (Bmab), cetuximab (Cmab), or panitumumab (Pmab). We employed a decision analysis method in combination with clinical and economic evidence. The health outcomes of the regimens were analyzed on the basis of overall and progression-free survival. The data were drawn from the literature on randomized controlled clinical trials of the above-mentioned drugs. The total costs of the regimens were calculated on the basis of direct costs obtained from the medical records of patients diagnosed with unresectable advanced or recurrent colorectal cancer at Yamagata University Hospital and Yamagata Prefecture Central Hospital. Cost eŠective-ness was analyzed using a Markov chain Monte Carlo (MCMC) method. The study was designed from the viewpoint of public medical care. The MCMC analysis revealed that expected life months and expected cost were 20 months/ 3,527,119 yen for mFOLFOX6, 27 months/8,270,625 yen for mFOLFOX6＋Bmab, 29 months/13,174,6297 yen for mFOLFOX6＋Cmab, and 6 months/12,613,445 yen for mFOLFOX6＋Pmab. Incremental costs per eŠectiveness ratios per life month against mFOLFOX6 were 637,592 yen for mFOLFOX6＋Bmab, 1,075,162 yen for mFOLFOX6＋Cmab, and 587,455 yen for mFOLFOX6＋Pmab. Compared to the conventional mFOLFOX6 regimen, molecular-targeted drug regimens provide better health outcomes, but the cost increases accordingly. mFOLFOX 6＋Pmab is the most costeŠective regimen among those surveyed in this study.
INTRODUCTION
The median survival time (MST) of unresectable advanced or recurrent colorectal cancer patients without any treatment is about eight months. 1) While MST has been extended to about two years owing to the progress in chemotherapy, 2, 3) complete remission remains di‹cult to achieve. The Guidelines for Colorectal Cancer Treatment 2016 recommends regimens with molecular-targeted drugs such as bevacizumab (Bmab), cetuximab (Cmab), and panitumumab (Pmab) in combination with conventional (‰uorouracil-based) regimens for patients appropriate for intensive therapy.
To select the optimal primary treatment, it is necessary for physicians to obtain informed consent from patients as per appropriate evidence on the expected health outcomes and cost eŠectiveness of possible regimens. Although the e‹cacy of each chemotherapy regimen is conˆrmed, there is no deˆnite conclusion as to which combination regimen is the most eŠective. 4 10) The regimen to be selected is left to the judgment of doctors and/or medical institutions. The present situation makes it necessary to evaluate regimens in terms of pharmacoeconomics.
Given its increasingly aging population and declining number of newborns, Japan's national medical expenditure has been annually growing and reached 40 trillion yen in 2013. The increasing proportion of medical expenditure is one of the most seriousˆnan-cial problems in the country. Reducing medical costs, especially medicinal supply costs, is inevitable. In particular, to use public medical resources properly, it is important to conduct an economic assessment using This study aims to analyze clinical decisions in the ‰uorouracil-oxaliplatin-levofolinate combination therapy (mFOLFOX6) and molecular-targeted agent combination therapies, which are representative regimens for unresectable advanced or recurrent KRAS-wild type colorectal cancer, to identify the most cost-eŠec-tive regimen on the basis of clinical and economic evidence.
METHOD

Analysis Model
This study was a retrospective observational study from the perspective of public medical care. A state transition model (Markov model) was developed to describe the clinical courses in the treatment of advanced or recurrent colorectal cancer (Fig. 1 ). The transition model represents three health states: continueˆrst-line (progress free), alive with progression or relapse (post-free), and death. In all the regimens in question, the dosage of mFOL-FOX6 was 5-FU 400 mg/m 2 , l-LV 200 mg/m 2 , and L-OHP 85 mg/m 2 on day 1 and 46-h, continuous, intravenous 5-FU 2400 mg/m 2 on days 1 and 2 (14 d/ cycle). The dosages of Bmab, Cmab, and Pmab were 5 mg/kg (day 1), 400 mg/m 2 (loading); 250 mg/m 2 (days 1 and 8); and 6 mg/kg (day 1), respectively. The expected health outcomes and costs until all patients died were estimated using the Markov model, 11) with each cycle being one-month long (Fig.  2) .
Health Outcomes Evaluation Based on the results of the randomized controlled clinical trials of advanced or recurrent colorectal cancer, we evaluated health outcomes (OS and PFS) of the regimens 4 10) and calculated transition probabilities between the three health states.
Resource Use and Costs We evaluated clinical decisions for patients newly diagnosed with advanced or recurrent colorectal cancer at Yamagata University Hospital or Yamagata Prefecture Central Hospital between January 2015, and December, 2016, and who followed a survey-targeted regimen as theˆrst-line treatment.
Medical records and receipts were used to examine the usage of drugs, tests, and medical supplies. The costs of regimens were calculated on the basis of direct costs, which included drug acquisitions (including drugs used for the prevention of adverse eŠects), tests, medical supplies, and personnel costs. The costs were estimated on the basis of the standard dosage of drugs and drug acquisition costs were based on the Japanese Drug Price Standard 2014. The cost data were collected during theˆrst to third cycles and the average cost per cycle was calculated.
Cost-eŠectiveness Evaluation
We calculated the total cost required for each regimen and examined the superiority of the molecular-targeted drug combination regimen over mFOLFOX6. We used the life months gained as the health outcome and calculated cost per eŠectiveness ratios (CERs) and incremental cost per eŠectiveness ratios (ICERs). TreeAge 2016 (TreeAge Software, Inc.) was used for the Markov model analysis.
ICER ＝
CER of a molecular-targeted drug regimen-CER of FOLFIRI expected lifetime of molecular-targeted drug regimen-expected lifetime of FOLFIRI Sensitivity Analysis
To conˆrm the in‰uence of the data used in our analysis, a sensitivity analysis was conducted. We performed a probabilistic sensitivity analysis using a Monte Carlo simulation with data uncertainty as probability distribution. Probabilistic sensitivity analysis was performed with a variation of ±10％.
Ethics Approval and Participation Consent This research was approved by the Ethics Commit- 85 YAKUGAKU ZASSHI Vol. 138, No. 1 (2018) tees at Yamagata University Medical School Hospital (approval number 61), and Ohu University School of Pharmaceutical Sciences (approval number 129).
The present study was conducted in compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects (February 28, 2017, partial revision) by the Ministry of Health, Labour and Welfare, Japan. Table 1 shows the transition probabilities between health states. With mFOLFOX6 alone, median PFS was 8.0 months (monthly probability: 0.0830) and median post-progression survival (PPS) was 11.9 months (0.0566). With the mFOLFOX6＋Bmab combination, median PFS was 10.2 months (0.0656) and median PPS was 16.7 months (0.0407). With the mFOLFOX6＋Cmab combination, median PFS was 9.1 months (0.0733) and median PPS was 18.4 months (0.0370). With the mFOLFOX6＋Pmab combination, the median PFS was 11.6 months (0.0580) and median PPS was 22.6 months (0.0302). The above results were incorporated in the Markov model (Fig. 2) .
RESULTS
Health Outcomes
Costs The subjects analyzed includedˆve patients who received mFOLFOX6 monotherapy, nine patients who were administered the Bmab combination, six patients who received the Cmab combination, andˆve patients who were given the Pmab combination. The backgrounds of these patients are presented in Table 2 . The cost of each regimen was 432,374 yen per month under mFOLFOX6, 787,117 1 (2018) yen in the Bmab combination, 1,361,340 yen for the Cmab combination, and 1,023,955 yen under the Pmab combination (Table 3) .
Cost EŠectiveness
The cost-eŠectiveness analysis of each regimen was conducted using the Markov model. The expected cost of mFOLFOX6 was 3,527,119 yen and the life month gained was 20.1 months. The expected costs of the Bmab, Cmab, and Pmab combination regimens were 8,270,625 yen, 13,174,629 yen, and 12,613,445 yen, respectively. The life months gained were 27.6 months, 29.1 months, and 35.6 months, respectively. The median ICERs of the Bmab, Cmab and Pmab combinations against mFOLFOX6 were 637,592 yen/month, 1,075,162 yen /month, and 587,455 yen/month, respectively ( Table  4 ). Figure 3 presents the results of 10,000 simulations using the MCMC analysis. Compared to mFOLFOX-6, the molecular-targeted drugs combined regimens are more eŠective but expensive.
Sensitivity Analysis Figure 4 and Table 4 present the results of the probabilistic sensitivity analysis. A re-analysis set to the upper and lower limits of the conˆdence interval had no in‰uence on the results.
DISCUSSION
In this study of primary treatments for unresectable advanced or recurrent colorectal cancer, it was conrmed that extended survival could be achieved by combining molecular-targeted drugs with conventional chemotherapy. However, it was also shown that acquisition costs would increase with the combination therapies. The median ICERs of Bmab, Cmab, and Pmab combinations against mFOLFOX6 were 637,592 yen / month, 1,075,162 yen / month, and 587,455 yen/month, respectively. In particular, the Cmab combined regimen proved to be the most expensive treatment strategy to obtain the same life month. Cmab must be administered every 7 d, while each of the other two molecular-targeted drugs is administered every 14 d. The short interdose interval results in the increased cost of Cmab combination therapy. The number of patients in this cost analysis was small. In order to resolve the uncertainty, 1 (2018) probabilistic sensitivity analysis was performed and it revealed that there was no in‰uence on the results. In addition, the cost in question is that of medical examination covered by health insurance and its in‰uence on the overall analysis can be considered slight.
In certain countries, ICER standards have been established for the allocation of the national healthcare insurance budget to new drugs. According to the National Institute for Clinical Excellence in the United Kingdom, the ICER should be within 20,000 30,000 pounds per quality-adjusted life year (QALY), 12) whereas in the United States, it should be within 50,000 100,000 dollars per QALY. 13) Although there are no clear standards deˆned in Japan, Shiroiwa et al. proposed that the ICER should be lower than 5 million yen per QALY, 14) that is, 416,666 yen per month. Based on this criterion, in the present case, the ICERs of all the molecular-targeted drug combination regimens against the mFOLFOX6 regimen exceed this limit, suggesting that they are not su‹ciently cost eŠective, although they have excellent e‹cacy when used in combination therapies. Note that these results can be applied to a broad range of cases because the costs were estimated as per the standard dosage. From an economic viewpoint, the moleculartargeted drug combination regimens should be selectively chosen as a primary treatment.
The ICER of the Pmab combined regimen was the lowest of the three combination regimens. Cmab and Pmab have been reported to be e‹cacious fromˆrst-to third-line therapies, but due to their dermal toxicity, they are often used only in secondary or tertiary treatments in actual clinical practice. However, our study suggests that the Pmab combination is the most cost-eŠective regimen among the molecular-targeted drug combinations. Given the increased number of colorectal cancer cases in Japan, the use of expensive molecular-targeted drugs may result in higher incremental costs, which will undeniably pose a largê nancial burden on the country. Therefore, it is necessary to integrate economic evidence with clinical evidence when making therapeutic decisions for cancer treatments, especially regarding expensive molecular-targeted drug therapies.
The current study has some limitations. First, it does not contain information about the adverse eŠects of treatment. We focused on the main eŠects of drugs and did not include information on the adverse events. If we could have obtained the utility weight of each frequent adverse eŠect, then the results would have been more detailed. Second, we only analyzed the optimalˆrst-line treatment, but second-line or later treatments also aŠect the overall survival in advanced colorectal cancer treatments. 15) Further research is needed to identify the optimal sequence of molecular-targeted therapies.
In recent years, there have been numerous outcome analyses that incorporate evaluation indices from a patient's viewpoint, 16, 17) instead of objective indices such as OS. Molecular-targeted drugs have contributed to the remarkable improvement in the prognostic outcomes of colorectal cancer treatments. This implies a higher PFS and, thus, the notion of QALY has become more important considering patients' quality of life is essential in the evaluation of regimens.
